



Financial Statements
for the 3rd quarter of fiscal year ending March 31, 2021
(From Apr. 1, 2020 to Dec. 31, 2020)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

February 8, 2021

Highlights in Business Results



(unit: JPY million)

	Apr. - Dec. 2019 Results	Apr. - Dec. 2020 Results	Diff.	Year-over-Year
Net sales	43,552	42,749	(803)	(1.8)%
Operating profit	1,497	1,673	175	11.8%
Ordinary profit	1,720	1,565	(155)	(9.0)%
Profit attributable to owners of parent	1,176	1,427	250	21.3%
Basic earnings per share	JPY 48.26	JPY 58.47	---	---

Exchange Rate (average during period)	US Dollar	108.67	106.11
	Euro	122.66	120.90
	(unit: JPY) Singapore Dollar	79.48	77.03

**Decreased in sales (2nd straight year) .
Increased in profit (3rd straight year) .**


Sales	Japan	-Increased sales of Closed Drug Mixing/Infusion System "NEO SHIELD" -Decreased sales of Infusion Sets	Profit	-Despite the decreased sales and the increase in R&D expense, operating profit increased due to the reduced selling cost
	Overseas	-Increased sales of Hemodialysis Machine for China and Blood bags for East Asia -Decreased sales of AV Fistula Needles for North America		-Ordinary profit decreased due to foreign exchange losses -The subsidy income of extraordinary income resulted in the increase of the profit attributable to owners of parent

Summary by segment (geographical area)

(unit: JPY million)

Japan

■ Sales incl. internal transaction
■ Sales for third party
— Profit



[Sales]


Increased sales of Hemodialysis Machines for China market and Closed Drug Mixing/Infusion System “NEO SHIELD” were offset by decreased sales of Infusion Sets, reducing net sales.

[Ordinary profit]

Despite the decreased selling cost, the influence of decreased sales and the increase in R&D expenses resulted in a reduced profit.

Singapore

■ Sales incl. internal transaction
■ Sales for third party
— Profit



[Sales]


Despite the increased sales of Blood bags for East Asia market, net sales reduced due to influence of foreign currency translation.

[Ordinary profit] The increase of labor cost and the influence of foreign exchange losses resulted in a reduced profit.

*This segment includes Indonesia local subsidiary.

China

■ Sales incl. internal transaction
■ Sales for third party
— Profit



[Sales]

Increased sales of Blood Purification Circuit for the Japan market raised net sales.


[Ordinary profit]

The influence of increased sales resulted in profit growth.

Summary by segment (geographical area)

(unit: JPY million)

Philippines




[Sales]

Increased sales of Apheresis kits for the North America market raised net sales.

[Ordinary profit]

The influence of increased sales resulted in an improved profit.

Germany




[Sales]

Despite the increased sales of AV Fistula Needle, net sales reduced due to influence of foreign currency translation.

[Ordinary profit]

The influence of foreign exchange losses resulted in a reduced profit.



Others





*This segment includes business activity of domestic subsidiaries, United States, South Korea and Thailand.

Sales by Business Segment

Apr. – Dec. 2019
 Apr. – Dec. 2020




Sales increase or decrease (Customer's Location)



Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Dec. 2019	Apr. - Dec. 2020	Diff.	Year-over-Year
Labor Cost	4,378	4,265	(113)	(2.6)%
Transport	1,288	1,324	35	2.8%
R & D	1,072	1,156	84	7.9%
Depreciation	264	252	(12)	(4.8)%
Others	3,073	2,649	(423)	(13.8)%
Total	10,077	9,648	(429)	(4.3)%

[Others] Travel expenses and advertising and promotion expenses decreased.

Ordinary profit : Compared with the previous year

(unit: JPY million)



Apr. - Dec. 2019

Apr. - Dec. 2020

Forecast for FYE Mar. 2021



(unit: JPY million)

	FYE Mar. 2020 Result	FYE Mar. 2021 Forecast	Year-over-Year
Net sales	58,569	59,500	1.6%
Operating profit	2,314	2,000	(13.6)%
Ordinary profit	2,672	2,200	(17.7)%
Profit attributable to owners of parent	1,977	1,600	(19.1)%
Basic earnings per share	JPY 81.12	JPY 65.62	---

Exchange Rate (average during period)	US Dollar	108.74	108
	Euro	122.07	120
	(unit: JPY) Singapore Dollar	79.28	78

Topics



-Received the "Good Design Award 2020" for three products
(Infusion Pump, Tongue Pressure Measuring Device and Centrifugal Blood Pump System).
Oct. 2020



-Launched a new Portable Electrocardiograph "myBeat Home ECG".
Oct. 2020



myBeat Home ECG

-Signed a mutual product supply agreement with Getinge Group Japan for
Cardiopulmonary related products.
Jan. 2021



Cardiopulmonary blood tubing sets
(Made by JMS)



Cardiopulmonary related products
(Made by Getinge)



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.